

VTE Prevention

Hospital patients need their clot risk checked with validated scoring tools, then given medicine or compression devices to stop blood clots from forming.

THE STORY IN ONE SENTENCE

Hospital patients need their clot risk checked with validated scoring tools, then given medicine or compression devices to stop blood clots from forming.

“Stop deadly clots before they start — score every patient's risk, then use blood thinners or leg pumps for anyone at medium or high risk.”

Normal anatomy — the body's job

Normally, blood flows steadily through your veins back to your heart, and a balanced clotting system seals cuts without forming clots inside healthy vessels.

BODY'S JOB

Your leg veins push blood upward against gravity using muscle squeezes and one-way valves. The endothelium (the smooth inner lining of your vessels) releases natural anti-clotting chemicals like prostacyclin and nitric oxide to keep blood liquid. Clotting factors (proteins made by your liver) and platelets (tiny sticky cells) float in the blood ready to form a plug only when a vessel tears. This balance — clot when injured, stay liquid inside intact vessels — is called hemostasis.

1. Leg muscles squeeze veins with each step, pushing blood upward toward the heart.
2. One-way valves in the veins snap shut so blood cannot fall backward.
3. The smooth endothelium releases anti-clotting signals to keep blood flowing freely.
4. Clotting factors and platelets circle in the bloodstream, inactive unless a vessel wall breaks.
5. When you cut yourself, exposed collagen under the vessel lining activates platelets and the clotting cascade to seal the leak, then anti-clotting enzymes (like plasmin) dissolve the clot once healing is done.

What breaks

Three things together — slow blood flow, vessel injury, and sticky blood (Virchow's triad) — tip the balance toward clotting inside veins even when there is no cut to seal.

CLINICAL TERM

Venous thromboembolism (VTE) risk rises when immobility (bed rest, long surgery, paralysis) slows venous return, when endothelial injury (surgery, central lines, trauma, infection) exposes pro-clotting surfaces, and when hypercoagulable states (cancer releasing tissue factor, estrogen from birth control or pregnancy, inherited clotting mutations like Factor V Leiden, inflammation raising fibrinogen) shift the clotting balance. The clot forms in a deep vein (most often the calf or thigh), then can break loose and embolize to the pulmonary arteries, causing PE.

How the body compensates

The body has no direct way to sense a forming clot in a leg vein, so vital signs stay normal and the patient feels fine until the clot breaks free and blocks the lungs — making prevention the only reliable defense.

1. {'step': 'A clot silently grows in a deep leg vein.', 'why': 'Deep veins have no pain nerves in their walls, so the clot itself is invisible to the patient; only if it grows large enough to swell the leg (blocking venous return) or inflames surrounding tissue will you see pain, warmth, or swelling (edema) — and even then, most DVTs cause no symptoms at all.'}
2. {'step': 'Vital signs remain completely normal.', 'why': 'A clot sitting in a leg vein does not drop blood pressure, does not speed the heart, and does not lower oxygen saturation — the body has no compensatory response because it does not yet know there is a problem.'}
3. {'step': 'The clot breaks free and travels to the lungs (pulmonary a traveling clot lodging in a vessel (embolism)).', 'why': 'Sudden movement, standing up, or spontaneous detachment sends the clot through the inferior vena cava, into the right heart, and out the pulmonary arteries where it lodges and blocks blood flow to part of the lung.'}
4. {'step': 'Now the body tries to compensate for blocked lung circulation.', 'why': 'The right ventricle pumps harder to push blood past the blockage (raising heart rate and jugular venous pressure), but if the clot is large, right-heart strain overwhelms compensation — blood pressure drops (obstructive shock), oxygen falls (ventilation-blood flow (perfusion) mismatch in the blocked lung), and the patient can arrest within minutes.'}

5. {'step': 'By the time symptoms appear, the window to prevent death is narrow.', 'why': 'Massive PE can cause sudden cardiac arrest or refractory low oxygen in the blood (hypoxemia) before treatment (thrombolytics, embolectomy) can even begin; smaller PEs may be survivable but still cause permanent pulmonary high blood pressure (hypertension) or recurrent traveling clots (emboli) if the source DVT is not treated.'}

Domino effect

1. Patient admitted to hospital with immobility, surgery, or active cancer. — Bed rest stops the calf-muscle pump; surgery injures vessels and triggers inflammation; cancer cells release tissue factor — all three parts of Virchow's triad are now present, tipping the balance toward clot formation in deep leg veins.
2. Clotting cascade activates in pooled venous blood. — Stagnant blood concentrates activated clotting factors (thrombin, Factor Xa); injured endothelium exposes tissue factor that ignites the extrinsic pathway; hypercoagulable states (high estrogen, genetic mutations, inflammation) amplify the cascade — fibrin strands cross-link and trap red cells, forming a solid clot anchored to the vein wall.
3. A clot in a deep leg vein (Deep vein thrombosis) (DVT) grows silently in the calf or thigh. — Most DVTs cause no symptoms because deep veins have no sensory nerves; even large clots may go unnoticed unless they completely block venous return and cause leg swelling, warmth, and pain (present in fewer than half of cases).
4. Clot fragment breaks free and embolizes to the pulmonary arteries (PE). — Sudden movement, straining, or spontaneous detachment sends part of the clot through the right heart into the lung circulation, where it lodges in a pulmonary artery branch and blocks blood flow to that part of the lung.
5. Blocked lung segment cannot exchange oxygen (V/Q mismatch). — The obstructed artery means no blood reaches the alveoli in that zone, so oxygen breathed into those air sacs cannot enter the bloodstream — ventilation without blood flow (perfusion) drops total body oxygen saturation and raises dead-space ventilation.
6. Right ventricle strains against the blockage; large PE causes shock and cardiac arrest. — The right ventricle is a thin-walled, low-pressure pump not built to overcome sudden high resistance — a massive clot spikes pulmonary artery pressure, dilates and stuns the right ventricle (acute cor pulmonale), drops left-heart filling (obstructive shock), and can trigger fatal arrhythmia or pulseless electrical activity within minutes.

7. Prevention with pharmacologic (heparin, enoxaparin, fondaparinux) or mechanical (sequential compression devices) prevention (prophylaxis) stops the cascade before the clot ever forms. — Low-dose anticoagulants inactivate Factor Xa or thrombin, keeping the clotting cascade below the threshold for spontaneous clot formation; compression devices squeeze the legs rhythmically to mimic walking and prevent venous stasis — both strategies break Virchow's triad and drop VTE incidence by 50–70 percent in hospitalized patients, saving thousands of lives every year.

Symptoms · what the patient feels, and why

- Recent surgery (especially hip, knee, belly, or cancer surgery): Surgery triggers the blood's clotting system — the body thinks it needs to stop bleeding, so it tips toward making clots. At the same time, lying still afterward means blood pools and slows down in the leg veins, which lets clots form. These two forces together raise the odds of a clot by 10 to 100 times depending on the surgery.
- Being stuck in bed for three or more days, or not able to move around much (from illness, injury, or stroke): When your legs don't move, the calf muscles aren't squeezing the veins to push blood back up to the heart. Blood slows down and pools in the deep leg veins, which makes it easier for a clot to form — like how water sitting in a puddle gets scummy while a flowing stream stays clean.
- Active cancer or getting chemotherapy: Cancer cells release chemicals that activate the clotting system, and chemotherapy can damage the walls of blood vessels and lower platelet numbers while also making the remaining platelets stickier. Both changes tip the blood toward clotting. People with cancer are four to seven times more likely to get a blood clot.
- Past blood clot (DVT or PE) in your own history: A clot in the past means your clotting system is already tipped toward making clots — either because you inherited genes that make your blood stickier, or because a vein was damaged and never fully healed. Either way, the risk of another clot jumps to about 10 to 15 percent over the next few years without prevention.
- Pregnancy or just gave birth (especially in the first six weeks after delivery): Pregnancy hormones (especially estrogen and progesterone) make the blood clot faster to protect the mother from bleeding too much during delivery. The growing uterus also presses on the big veins in the belly, slowing blood flow from the legs. After delivery, clotting factors stay high for weeks while the body heals. Risk peaks in the first three weeks postpartum.

- Using birth-control pills or hormone replacement therapy (estrogen): Estrogen raises levels of clotting proteins made by the liver (like fibrinogen and factor VII) and lowers natural anticlotting proteins (like protein S). This shifts the balance toward clotting. Pills that combine estrogen and progestin raise clot risk about three to four times; the highest risk is in the first year of use.
- Long travel (plane, car, or train ride longer than four hours) where you sit still: Sitting cramped with your knees bent for hours squeezes the veins behind the knee and slows blood flow back from the lower leg. Without muscle movement to pump blood upward, it pools and can clot — especially if you're also dehydrated, which makes the blood thicker. Risk doubles after flights over four hours.
- Obesity (BMI over 30): Extra body fat releases low-level inflammation signals (like IL-6 and TNF-alpha) that activate clotting factors. Higher belly pressure also squeezes the big veins and slows blood return from the legs. Together these double or triple clot risk compared to normal weight.
- Age over 60: As you age, the walls of veins lose stretchiness and valves that keep blood moving upward get weaker, so blood pools more easily. Clotting factors also rise a bit, and the body clears clots more slowly. Each decade after 60, clot risk roughly doubles.
- Central venous catheter (a large IV line in the chest or neck): The catheter irritates the inner wall of the vein, which triggers the clotting system to patch the 'injury.' Clots can form on the catheter itself and then grow to block the vein. About 5 to 10 percent of central lines cause a clot within weeks.

Focused exam

- One leg is swollen, warm, or tender in the calf or thigh: This is a sign of a clot in a deep leg vein (deep vein thrombosis) (a clot forming in a deep leg vein). The whole point of VTE prevention is to stop this clot from forming in the first place. If you see it, prevention has failed and treatment must start immediately.
- Shortness of breath or sharp chest pain that gets worse when taking a deep breath: These are red flags for pulmonary embolism (a clot lodging in a lung artery) (a clot that broke loose from the leg and is now blocking a lung artery). This is the life-threatening complication VTE prevention is designed to prevent. The patient needs oxygen and imaging right now.
- Patient is lying flat in bed and not walking — after surgery, injury, or severe illness: When blood sits still in the deep leg veins instead of moving, it clots. This is the upstream cause of DVT. VTE prevention means getting the patient up and walking early, or using leg-compression devices to keep blood moving.

- Active bleeding from the stomach, gums, surgical wound, or dark tarry stool: Tells you whether it is safe to give blood-thinning medicine. If bleeding risk is high, you use mechanical devices (leg compressors) only, not medication, to avoid making bleeding worse.
- Recent cancer diagnosis, major surgery in the past month, or use of estrogen-containing birth control or hormone therapy: These are major risk factors that make the blood more likely to clot. Cancer releases clotting triggers into the bloodstream, surgery damages blood vessels and activates clotting, and estrogen raises the liver's production of clotting proteins. Patients with these risks need stronger or longer VTE prevention.
- New cramping or stiffness in one leg that started after a long period of lying down or sitting still: This is an early warning sign of DVT. In VTE prevention, you catch this symptom and start treatment before the clot grows or breaks loose and travels to the lung.

Diagnostics · every test answers a question

- Complete blood count (CBC) with platelet count → Is the platelet count high enough to allow blood-thinning medication safely?
- Serum creatinine and estimated glomerular filtration rate (eGFR) → Are the kidneys working well enough to clear blood-thinning drugs safely?
- Prothrombin time (PT) and international normalized ratio (INR) → Is the patient's blood already thinned by other medication or liver disease?
- D-dimer blood test → Is there active clotting and breakdown happening in the body right now?
- Compression ultrasound of the leg veins → Is there a clot blocking a deep vein in the leg right now?
- Chest computed tomography angiography (CT-PE protocol) → Is there a clot blocking an artery in the lungs?

Treatment logic

- Risk stratification at hospital admission using a validated scale (Padua Prediction Score for medical patients, Caprini Score for surgical patients) → Identifies which patients are at medium or high risk for clots and therefore need blood-thinning medication, versus low-risk patients who only need mechanical devices. This ensures you give the right prevention to the right person and avoid over-treating or under-treating.
- Early mobilization (getting the patient out of bed and walking) and sequential compression devices (inflatable sleeves that squeeze the legs every few seconds) for all hospitalized patients → Squeezing the legs pushes blood out of the deep veins and back toward the heart, preventing it from pooling and clotting. Walking does the same thing naturally by using the calf muscles to pump blood upward.

- Low-molecular-weight heparin (enoxaparin 40 mg injected under the skin once daily) or unfractionated heparin (5,000 units injected under the skin every 8 or 12 hours) for medium- or high-risk medical or surgical patients → Blocks factor Xa and thrombin (the final two steps in the clotting cascade), so the blood stays thinner and clots cannot form in the deep veins or travel to the lungs. This is the core of VTE prevention for at-risk patients.
- Extended prevention (prophylaxis) with low-molecular-weight heparin or a direct oral anticoagulant (rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily) for 14 to 35 days after major orthopedic surgery (hip or knee replacement) → Keeps clotting factors suppressed during the highest-risk window after surgery, when the body's clotting system is hyperactive from surgical trauma and the patient is still not fully mobile. This cuts the rate of late clots that form after hospital discharge.
- Low-molecular-weight heparin or direct oral anticoagulant for hospitalized cancer patients; hold medication if active bleeding or platelet count below 50,000 → Cancer cells release tissue factor and microparticles that hyperactivate the clotting cascade. Blood thinners suppress this excessive clotting response and prevent DVT and PE while the cancer is being treated.
- Use mechanical compression devices only (no blood-thinning medication) if bleeding risk is very high — recent brain or spinal surgery, active stomach or intestinal bleeding, platelet count below 50,000, or severe liver disease → Avoids life-threatening bleeding from blood thinners while still using leg compression to keep some blood flow moving and reduce (but not eliminate) clot risk. This is a safer option when medication could cause catastrophic bleeding.
- Inferior vena cava (IVC) filter placement for patients with proven DVT or PE who cannot take any blood thinners due to active bleeding → A small metal cage is placed in the large vein that carries blood from the legs to the heart. It catches clots before they reach the lungs, preventing fatal pulmonary embolism (a clot lodging in a lung artery) when medication is not an option.

Medications

Enoxaparin (Lovenox) · Low-molecular-weight heparin (LMWH)

Enoxaparin blocks Factor Xa, a protein in the blood that helps clots form. By stopping Factor Xa, the drug keeps the clotting chain from moving forward, so new clots cannot build. It works in the blood itself, not in any single organ.

1. Enoxaparin binds to antithrombin, a natural brake on clotting that the body already makes.
2. This combination locks onto Factor Xa and stops it from working.
3. Without Factor Xa, the next step in the clotting chain (making thrombin, the clot glue) cannot happen.

4. Blood stays thinner and clots do not form as easily in veins where flow is slow.

SAFETY WATCH

Bleeding is the main risk—watch for unusual bruising, blood in urine or stool, or bleeding that will not stop. · Platelet count must be checked because rarely the drug can cause a dangerous drop in platelets (heparin-induced a low platelet count (thrombocytopenia), or HIT). · Kidney function matters—the drug leaves the body through the kidneys, so people with weak kidneys may need a lower dose or a different drug. · Do not use if someone is actively bleeding heavily or has very low platelets to start. · Spinal or epidural procedures (like spinal taps or epidurals for pain) carry a risk of bleeding around the spinal cord if done too close to a dose.

Unfractionated heparin (UFH) · Unfractionated heparin

Unfractionated heparin blocks both Factor Xa and thrombin, two key proteins in the clotting chain. By stopping both, it keeps the blood from making clots. It works in the bloodstream and is given through an IV or under the skin.

1. Heparin binds to antithrombin, making it thousands of times stronger.
2. The boosted antithrombin locks onto Factor Xa and thrombin, shutting them down.
3. Without Factor Xa, prothrombin cannot turn into thrombin.
4. Without thrombin, fibrinogen cannot turn into fibrin (the threads that weave a clot together).
5. Blood stays less sticky and clots do not form in veins where blood pools.

SAFETY WATCH

Bleeding risk—watch for blood in urine, stool, or unusual bruising. · Platelet count must be checked regularly because heparin can trigger HIT (a reaction where platelets drop and dangerous clots form). · The dose must be watched closely with blood tests (aPTT) to keep it in a safe range—too much causes bleeding, too little does not protect. · Do not use if someone is actively bleeding or has very low platelets. · Spinal or epidural procedures carry a risk of bleeding around the spinal cord.

Fondaparinux (Arixtra) · Synthetic Factor Xa inhibitor

Fondaparinux is a man-made version of a natural sugar chain that boosts antithrombin. It blocks only Factor Xa, stopping the clotting chain early. It works in the bloodstream and is given as a shot under the skin once a day.

1. Fondaparinux binds to antithrombin and makes it much more powerful.
2. The supercharged antithrombin locks onto Factor Xa and shuts it off.

3. Without Factor Xa, thrombin cannot form.
4. Without thrombin, the blood cannot weave fibrin threads into a clot.
5. New clots are blocked, especially in slow-moving veins.

SAFETY WATCH

Bleeding—watch for blood in urine or stool, heavy bruising, or bleeding that will not stop. · Kidney function is critical—the drug is cleared by the kidneys, so people with severe kidney disease cannot use it. · Do not use if someone is actively bleeding or has very weak kidneys (creatinine clearance under 30). · Spinal or epidural procedures carry a risk of bleeding around the spinal cord if done too close to a dose.

Rivaroxaban (Xarelto) · Direct oral anticoagulant (DOAC), Factor Xa inhibitor

Rivaroxaban directly blocks Factor Xa without needing antithrombin. It is a pill taken by mouth, so no shots are needed. By stopping Factor Xa, it keeps the clotting chain from moving forward.

1. Rivaroxaban locks onto the active site of Factor Xa, the pocket where it normally does its job.
2. With Factor Xa blocked, prothrombin cannot turn into thrombin.
3. Without thrombin, fibrinogen stays loose and does not weave into fibrin threads.
4. Blood stays thinner and clots do not form in veins where flow is sluggish.

SAFETY WATCH

Bleeding—watch for blood in urine, stool, heavy periods, or bruising. · Take with food (especially the 15 mg and 20 mg doses) to help the body absorb it fully. · Kidney function matters—dose must be lowered or the drug avoided if kidneys are weak. · Do not use if someone is actively bleeding or has severe liver disease. · Drug interactions—some medications (like strong antifungals or HIV drugs) change rivaroxaban levels and can make bleeding more likely. · Spinal or epidural procedures carry a risk of bleeding around the spinal cord if done too close to a dose.

Apixaban (Eliquis) · Direct oral anticoagulant (DOAC), Factor Xa inhibitor

Apixaban directly blocks Factor Xa, just like rivaroxaban, without needing antithrombin. It is a pill taken twice a day. By stopping Factor Xa, it keeps the blood from making new clots.

1. Apixaban binds to the active pocket of Factor Xa and locks it shut.
2. With Factor Xa blocked, prothrombin cannot become thrombin.
3. Without thrombin, fibrinogen cannot turn into fibrin threads.

4. Blood stays less sticky and clots cannot form easily in slow-flowing veins.

SAFETY WATCH

Bleeding—watch for blood in urine, stool, heavy bruising, or bleeding that will not stop. · Kidney function and weight matter—dose may be lowered if kidneys are weak, the person is very old, or they weigh less than 60 kg. · Do not use if someone is actively bleeding or has severe liver disease. · Drug interactions—some medications (like strong antifungals, HIV drugs, or seizure medicines) change apixaban levels and affect bleeding risk. · Spinal or epidural procedures carry a risk of bleeding around the spinal cord if done too close to a dose.

Aspirin · Antiplatelet agent

Aspirin blocks an enzyme inside platelets called COX-1, which platelets need to make thromboxane A2 (a chemical that tells platelets to stick together). With less thromboxane, platelets are less sticky and clots form more slowly. Aspirin is weaker than the other clot-prevention drugs, so it is used only in some hip or knee replacement patients as an alternative when bleeding risk is high or the patient does not want injections.

1. Aspirin enters the platelet and permanently shuts off COX-1.
2. Without COX-1, the platelet cannot make thromboxane A2.
3. Without thromboxane A2, the platelet gets a weaker signal to clump together.
4. Platelets are less sticky, so clots form more slowly—but they can still form if the clotting proteins (like Factor Xa and thrombin) are active.

SAFETY WATCH

Stomach irritation and ulcers—aspirin can damage the stomach lining over time. · Bleeding—watch for blood in stool (black or tarry stools), blood in vomit, or easy bruising. · Do not use if someone has active bleeding, a stomach ulcer, or severe liver disease. · Rarely, aspirin can trigger severe allergic reactions or asthma attacks in sensitive people.

Mechanical prevention (prophylaxis) (intermittent pneumatic compression devices, graduated compression stockings) · Non-drug prevention

These devices squeeze the legs gently and rhythmically to keep blood moving through the veins. When blood flows instead of pooling, clots are less likely to form. They are used when bleeding risk is too high for blood thinners, or alongside blood thinners for extra protection.

1. The device inflates, squeezing the calf or thigh muscles.
2. The squeeze pushes blood out of the deep veins and up toward the heart.
3. The device deflates, and blood flows back down to refill the veins.

4. This cycle repeats, keeping blood moving instead of sitting still.
5. Moving blood is less likely to clot than blood that pools in one spot.

SAFETY WATCH

Do not use on a leg that already has a clot (DVT)—squeezing could break off a piece and send it to the lungs. · Do not use if the leg has severe swelling, infection, or skin wounds where the device sits. · Check skin under the device for pressure sores or irritation. · Devices must fit properly—too tight can hurt, too loose does not help.

Red flags

- Sudden shortness of breath, fast breathing, or chest pain that gets worse with a deep breath (could mean a clot has broken off and traveled to the lungs — a pulmonary embolism (a clot lodging in a lung artery) — which can be deadly)
- One leg is swollen, painful, red, and warm compared to the other leg (sign of a a clot in a deep leg vein (deep vein thrombosis) or DVT forming right now)
- Coughing up blood or bloody mucus (can mean a clot in the lung has damaged the tissue)
- Fainting, feeling dizzy, or heart racing with shortness of breath (signs that a big clot in the lung is blocking blood flow and dropping blood pressure — life-threatening)

Nursing priorities

1. Complete VTE risk assessment using a validated tool like Padua Prediction Score or Caprini Score within four hours of hospital admission — Risk stratification (sorting patients by clot danger) identifies who needs blood thinners versus mechanical prevention only; missing high-risk patients leads to preventable clots that cause death or permanent lung damage
2. Apply sequential compression devices to both legs immediately for all patients unless they have acute DVT or severe peripheral artery disease — SCDs (leg squeeze machines) push blood out of leg veins every minute, preventing stasis (pooling) that triggers clot formation; they work within hours and have almost no bleeding risk
3. Assist patient out of bed and ambulate in hallway at least three times per day starting on day one of admission — Walking contracts calf muscles which pump blood back to the heart and prevent venous stasis; even two-minute walks reduce VTE risk by 30 percent compared to bedrest
4. Administer ordered pharmacologic prevention (prophylaxis) at the correct time every day, holding doses only for active bleeding or platelet count below 50,000 — LMWH (low molecular weight heparin like enoxaparin) or UFH must reach steady blood levels to block clotting factor Xa; missed doses create gaps where clots can form in hours

5. Monitor injection sites for a pooled collection of blood (hematoma) (blood pocket under skin) and check complete blood count every two to three days while on heparin — Heparin can cause HIT (heparin-induced a low platelet count (thrombocytopenia), a dangerous drop in platelets) in 1 to 3 percent of patients, usually between days 5 and 10; this paradoxically causes both clots and bleeding
6. Teach patient to report leg swelling, pain, warmth, or redness and any sudden chest pain or shortness of breath immediately — Early DVT symptoms appear before clots break off and travel to lungs; catching DVT in the leg stage prevents PE which kills 10 to 30 percent of patients even with treatment
7. Ensure adequate hydration with at least 1500 mL oral or IV fluid daily unless heart failure limits fluids — Dehydration (low body water) thickens blood and raises hematocrit (red cell percentage), increasing viscosity (thickness) that slows venous flow and promotes clot formation
8. Document and communicate VTE prevention (prophylaxis) plan at every handoff and verify continuation orders if patient transfers units or goes for procedures — Prevention (Prophylaxis) gaps during transfers account for 40 percent of hospital-acquired VTE; clots can form within 24 hours when prevention stops

Sources

- American Society of Hematology VTE prevention guideline 2018
- American College of Chest Physicians antithrombotic guideline (ACCP) 2012
- American College of Obstetricians and Gynecologists VTE in pregnancy guideline 2018
- Cochrane systematic reviews on thromboprophylaxis

Last reviewed: 2026-07-07